Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of Apixaban vs Warfarin for prevention of stroke and systemic embolism in nonvalvular atrial fibrillation
2006-002147-91Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of apixaban in Atrial fibrillation (AFib) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Time to first occurrence of confirmed stroke or systemic embolism. Started Feb 2007; status: completed.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2006-002147-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002147-91.